Navigation Links
Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
Date:3/30/2009

- U.S. FDA approves Intercell's first marketed product, a new vaccine against Japanese Encephalitis for travelers and military personnel

- Commercial product launch in the U.S. planned for Q2 2009

VIENNA, March 30 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that the U.S. Food and Drug Administration (FDA) approved IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE). The initial target for use of Intercell's vaccine - the only such product currently manufactured for the U.S. market - will be adult travelers and military personnel who visit or are deployed to affected countries, including India, China, and other parts of Asia.

"This approval is a major achievement for Intercell, and it marks a significant milestone in this company's history. The approval of IXIARO by the FDA - part of a regulatory process that included parallel filings in Europe and Australia - puts us in a select group of biotechnology companies with both an FDA-approved product and an outstanding pipeline of promising vaccine candidates," said Intercell's Chief Executive Officer, Gerd Zettlmeissl. "With this decision, Americans - both civilians and military personnel - will have an efficacious and safe way to protect themselves from the devastating and deadly effects of Japanese Encephalitis."

JE is a deadly infectious disease found mainly in Asia. Approximately 30,000 to 50,000 cases of JE are reported in Asia each year, and the actual number of cases are likely much higher due to underreporting in rural areas. JE is fatal in approximately 30 percent of those who show symptoms and leaves half of survivors with permanent brain damage. As there is no specific treatment for JE, vaccination is the only highly effective protection for the millions of travelers and military personnel who live in or travel to areas where the virus circulates.

Intercell's vaccine is a purified, i
'/>"/>

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
2. Iomai Stockholders Approve Merger With Intercell Subsidiary
3. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
4. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
5. Spherix Announces 2008 Financial Results
6. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing
7. SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY
8. Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
9. Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders
10. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
11. International Isotopes Inc. Announces Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life ... and products for advanced microarray diagnostics, today announced ...  to its Management team. In his capacity as ... transition from a development stage to a commercially ... the Company,s capital market strategy and to secure ...
(Date:3/3/2015)... LITTLE FALLS, N.J. , March 3, 2015 /PRNewswire/ ... a biotechnology company specializing in the development of and ... of damaged tissues and organs, announced today that it ... Purchase Agreement with Amarantus Bioscience Holdings, Inc. (OTC Bulletin ... required under the Agreement, Amarantus made the final payments ...
(Date:3/3/2015)... 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... journal, Expert Opinion on Biological Therapy , Dr. ... Zhenggang Zhang , at the Henry Ford Hospital in ... beta 4 (TB4) has the capacity to promote CNS ... more post-injury, leading to neurological recovery in each case.  ...
(Date:3/3/2015)... 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... the lives of pets, announced today that it will release ... 12, 2015 after the market close. The Company will host ... Interested parties may access the call by ... internationally, and using conference ID 98449349.  The ...
Breaking Biology Technology:SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... May 26 , - Production Increase Brings ... Therapeutics (Euronext: AMT), a leader in the field,of ... a Cooperative,Research and Development Agreement from the National ... Institutes of Health (NIH), Bethesda,Maryland, that promises to ...
... AMLN ) will Web cast its Annual Meeting ... PT from the company,s corporate,headquarters in San Diego, CA. ... Executive Officer of Amylin Pharmaceuticals,will be providing a corporate ... and a recording will be made,available following the event. ...
... - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ... Patent 2,360,833 entitled "Reovirus for the Treatment ... use of one or more,recombinant reoviruses to ... provides the Company with additional patent protection ...
Cached Biology Technology:AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 2AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 3Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent 2
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... for months after a traumatic brain injury (TBI), revealing ... new research led by the University of Melbourne, Australia ... Neurotrauma Initiative is published in the latest issue of ... Around 400,000 Australians have a disability related to traumatic ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... results on Wednesday, November 10, 2010 after the markets close. PDL,s ... Eastern Time to discuss the financial results.   ... call via phone, please dial (866) 271-5140 from the United States ...
... HAGUE (2 November 2010)A unique acacia known as a "fertilizer ... maize yields in smallholder agriculture in Zambia and Malawi, according ... The findings were central to the arguments of agroforestry experts ... technology more widely throughout the African nations most vulnerable to ...
Cached Biology News:Study provides treatment hope for long term effects of brain trauma 2PDL BioPharma to Announce Third Quarter 2010 Financial Results on November 10, 2010 2Scientists find that evergreen agriculture boosts crop yields 2Scientists find that evergreen agriculture boosts crop yields 3
HES-1 [Hairy 1], Available Summer 2003...
E1A (adenovirus early region 1)...
... 1 ( Abpromise for all tested ... peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK EDILYHFNLT TSRHNFPALF GDVKFVCVGG ... acids 1-99 of Human Uridine Phosphorylase 1 ... 7378 Swiss Protein ID: ...
Nucleobindin 1 [NUCB1]...
Biology Products: